Compass Therapeutics, Inc. (CMPX) SEC Filings & Earnings Calls

Regulatory setback: FDA requires additional survival trial, delaying BLA submission and increasing development costs and timeline uncertainty.

“FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.” · word for word

No product revenue; history of operating losses

“We have incurred significant operating losses since inception and have not generated any revenue from the sale of products and we do not expect to generate any revenue from the sale of products in the near future, if at all.” · word for word

Dependence on regulatory approval for tovecimig

“We expect feedback from the FDA in the third quarter regarding the COMPANION-002 Phase 2/3 data, prior to a potential BLA filing later this year.” · word for word

OS did not meet statistical significance

“Secondary endpoint analyses of overall survival (OS) were confounded by both high crossover (54%) and notably prolonged survival in crossover patients randomized to the control arm then treated with tovecimig and, therefore, did not meet statistical significance.” · word for word

Regulatory and clinical risk for tovecimig BLA

“FDA feedback expected Q3 2026; no guarantee of approval.”

Increasing net loss and expenses

“Net loss increased 26.6% YoY; R&D and G&A expenses rising.”

Clinical and regulatory risk remains; BLA approval not guaranteed.

“Drugs under clinical investigation, not yet approved by FDA. Forward-looking statements subject to risks.”

No product revenue; history of losses

“We have incurred significant operating losses since inception and have not generated any revenue from the sale of products and we do not expect to generate any revenue from the sale of products in the near future, if at all.” · word for word

Dependence on regulatory approval

“We intend to meet with the U.S. Food and Drug Administration (“FDA”) to discuss these data in advance of a planned BLA submission.” · word for word

Need for additional funding

“We expect that we will require additional funding to complete the clinical development of these programs including the payment of developmental milestones, commercializing our product candidates, if we receive regulatory approval, and pursuing in-licenses or acquisitions of other product candidates.” · word for word

Clinical trial risk: tovecimig OS data confounded by crossover

“OS analysis confounded by high crossover from control arm (n=31)”

Pre-revenue biotech with no approved products; net loss of $66.5M in FY2025.

“Net Income (in thousands) (8) (g) ... 2025 ... (66,489)”

OS endpoint not met due to high crossover (54%); regulatory path uncertain despite positive ORR and PFS.

“OS HR=1.05, p=0.78; high crossover 54%.”

No approved products

“We have a limited operating history and no products approved for commercial sale.” · word for word

Need for additional financing

“We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all.” · word for word

Clinical trial uncertainty

“Clinical development involves a lengthy and expensive process with uncertain outcomes.” · word for word

Increasing net loss and R&D spend may pressure cash runway.

“Net loss increased to $66.5M from $49.4M; R&D expenses up 32% to $56M.”

Clinical trial outcomes uncertain; tovecimig data expected in April.

“Tovecimig PFS/OS data expected in April 2026; could be transformational.”

Clinical trial risk: tovecimig PFS/OS data expected late Q1 2026; failure could impact pipeline value.

“The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig.” · word for word

Regulatory risk: CTX-8371 accelerated pathways for HL are investigational; no guarantee of approval.

“the Company is now investigating potential accelerated pathways to approval for the treatment of both adult and pediatric patients with HL in the post-checkpoint inhibitor setting.” · word for word

Increasing net loss and R&D spend with no revenue.

“Net loss $14.3M vs $10.5M YoY; R&D expenses up 49%.”

Clinical trial risk; data readouts may not meet expectations.

“Pipeline milestones dependent on clinical data; OS/PFS data expected late Q1 2026.”

No revenue from product sales

“We have incurred significant operating losses since inception and have not generated any revenue from the sale of products and we do not expect to generate any revenue from the sale of products in the near future, if at all.” · word for word

Need for additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Clinical trial risk

“The successful development and commercialization of product candidates is highly uncertain.” · word for word